Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - Powell Max Limited (PMAX) is up 38% at $3.15 [3] - Kaixin Holdings (KXIN) is up 34% at $4.16 [3] - SMX (Security Matters) Public Limited Company (SMX) is up 16% at $59.02 [3] - Anixa Biosciences, Inc. (ANIX) is up 14% at $4.80 [3] - American Eagle Outfitters, Inc. (AEO) is up 12% at $23.41 [3] - POET Technologies Inc. (POET) is up 11% at $5.21 [3] - Massimo Group (MAMO) is up 11% at $4.72 [3] - Marvell Technology, Inc. (MRVL) is up 10% at $102.60 [3] - Capricor Therapeutics, Inc. (CAPR) is up 8% at $6.92 [3] - Tharimmune, Inc. (THAR) is up 6% at $2.53 [3] Premarket Losers - Acadia Healthcare Company, Inc. (ACHC) is down 31% at $11.25 [4] - Aethlon Medical, Inc. (AEMD) is down 26% at $3.56 [4] - Polyrizon Ltd. (PLRZ) is down 19% at $5.92 [4] - CervoMed Inc. (CRVO) is down 16% at $6.85 [4] - TryHard Holdings Limited (THH) is down 15% at $19.01 [4] - Pure Storage, Inc. (PSTG) is down 14% at $80.93 [4] - AlphaTime Acquisition Corp (ATMC) is down 14% at $10.62 [4] - Leslie's, Inc. (LESL) is down 13% at $3.11 [4] - Lulu's Fashion Lounge Holdings, Inc. (LVLU) is down 11% at $4.56 [4] - Vistagen Therapeutics, Inc. (VTGN) is down 5% at $3.39 [4]

Company Performance - Neonode Inc. experienced a stock price drop of approximately 68.34%, closing at $6.81, down from a year high of $29.9, influenced by market reactions to company developments and industry trends [2][8] - Artelo Biosciences saw a 50.34% decrease in its stock price, closing at $4.35, amid ongoing clinical trials and a public offering priced at $3 million [3][8] - 707 Cayman Holdings Limited faced a 48.45% decline in its stock price to $0.39, potentially due to challenges in the retail sector and exploring a crypto treasury reserve with Precious Choice Global Limited [4][8] - Aethlon Medical's stock price fell by 45.76% to $0.73, possibly linked to recent performance updates and investor sentiment towards the healthcare sector, with a public offering valued at $4.5 million [5] - Purple Biotech's stock price decreased by 43.54%, closing at $0.80, which may be related to clinical trial results and market conditions affecting biotech firms [6] Market Trends - The significant price movements of these companies highlight the importance of monitoring market trends, company developments, and broader economic factors that can impact stock performance [7]

Core Insights - Aethlon Medical's Hemopurifier® shows expanded therapeutic potential beyond virology and oncology, particularly in organ transplantation [1][2] - A preclinical study published in Transplant Immunology demonstrates the Hemopurifier's ability to remove extracellular vesicles (EVs) and microRNAs from discarded donor kidneys, which may improve kidney function post-transplant [1][2] - The company is currently focused on oncology trials in Australia and India, but the new data suggests a broader application for the Hemopurifier in organ preservation [2][3] Company Overview - Aethlon Medical is a therapeutic company developing the Hemopurifier, designed to combat cancer, life-threatening viral infections, and for organ transplantation [3] - The Hemopurifier has received FDA Breakthrough Device designation for treating advanced or metastatic cancer and life-threatening viruses [3] Research Findings - The preclinical study indicates significant reductions in EVs and microRNAs associated with renal dysfunction when using the Hemopurifier on perfusion fluid from discarded kidneys [2] - The study supports the hypothesis that EVs and microRNAs contribute to complications in kidney transplantation, such as delayed function and organ rejection [2] Future Directions - Further evaluation of the Hemopurifier's integration into machine perfusion circuits for discarded kidneys is necessary, with plans for clinical trials to assess its efficacy [2][3] - The technology could potentially enhance existing organ preservation methods, indicating a "pipeline within a device" for future therapeutic applications [2]